Apha slides tfah hep b &c levi slides[1]
-
Upload
apha-alcohol-tobacco-other-drugs-section -
Category
Health & Medicine
-
view
308 -
download
1
Transcript of Apha slides tfah hep b &c levi slides[1]
HBV and HCV: America’s Hidden Epidemics
Jeffrey Levi, PhD
Trust for America’s Health
October 14, 2010
Who We Are
Trust for America’s Health (TFAH) is a non-profit, non-partisan organization dedicated to saving lives by protecting the health of every community and working to make disease prevention a national priority.
Goals of the Report Follow-on to IOM report Concrete strategies for federal action Unique opportunities right now through
Affordable Care Act and scientific breakthroughs
Overview of Problem There are a number of unique challenges that must
be addressed when combating the hepatitis B virus (HBV) or hepatitis C virus (HCV), including: health complications that take decades to develop; significant social stigmas connected to the viruses; disproportionately impacts racial, ethnic and sexual
minorities; and infectious disease prevention strategies have traditionally
been siloed.
Key Findings Nearly two percent of the U.S. population may have
some form of the disease – and approximately five million of these individuals will develop a chronic form of the diseases.
An estimated 65 to 75 percent of the five million Americans currently infected with HBV or HCV do not even know they have the virus.
Impacts on Diverse Populations Of the more than five million Americans with HBV
or HCV: Baby Boomers account for two-thirds of HCV cases - and
if left untreated, it could lead to a major increase in upcoming Medicare spending;
African Americans account for 22 percent of HCV cases; Asian and Pacific Islander Americans account for 50
percent of HBV cases; and Gay and bisexual men account for 15 percent to 25
percent of new HBV cases and are at increased risk for HCV infection.
Once-in-a-Generation Opportunity New prevention options and
treatment possibilities due toPatient Protection and Affordable Care Act (ACA).
Scientific breakthroughs will make treatment, vaccination easier.
Key Recommendations Tracking hepatitis to better target
prevention and treatment efforts: Build on existing HIV surveillance systems;
strengthen state and local networks Focus on tracking both cumulative cases and
emerging outbreaks
Assure that emerging electronic health record system collects appropriate hepatitis-related data
Better tracking of new outbreaks
Key Recommendations HBV and HCV screening and HBV
vaccinations should be the standard of care in the reformed health care system: Screen based on risk factors and age
Make this part of initial Medicare visit and essential health benefit under health reform
Reach out to non-traditional settings HBV vaccination should be encouraged as part of
the preventive benefit under health reform and monitored through electronic health records
Key Recommendations Improve treatment by ensuring everyone who is
diagnosed is linked to care and receives the standard of care: Appropriate coverage and reimbursement for treatment Public-private treatment guidelines updated regularly Plans under Exchanges as well as Medicare and Medicaid
required to meet treatment guidelines and have networks with qualified providers of hepatitis care
Improve referral systems Expand access to wraparound services, perhaps through
Ryan White Program
Key Recommendations Assure adherence to treatment:
Treatment requires a continuum from point of screening throughout care
Provide appropriate culturally and linguistically sensitive support services
Special consideration for marginalized populations
Key Recommendations Prevent New Infections:
Eliminate newborn HBV infections CMS-CDC joint initiative
Eliminate health care-associated HBV and HCV infections
Promote universal HBV vaccination Bolster prevention campaigns and public awareness
Key Recommendations Strengthen research agenda:
Single dose HBV vaccine; develop HCV vaccine; simplify treatment options; rapid tests
Funding proportionate to public health risk NIH funding for hepatitis research is ~$150 million
The cost of doing nothing 150,000 Americans could die from liver
cancer or end-state liver disease (IOM) Medical costs for HCV patients could double
over the next 20 years from $30 billion to $80 billion (Milliman) Many of these costs will be borne by Medicare
and Medicaid A comprehensive approach that includes early
diagnosis and treatment can reverse this trend
Questions?
Please contact: Dara Lieberman, Government Relations Manager
[email protected], 202-223-9870 x. 20 Visit TFAH online at www.healthyamericans.org